Creasman is the J. HRT has long been contraindicated in women who have—or have had—breast cancer. Here, the author examines the effects estrogen has on the breast and reviews several studies that suggest HRT actually may be of benefit to these women. This year, almost 50, women under the age of 50 will develop breast cancer. Most will undergo chemotherapy and become amennorhic. It is well known that premature surgical menopause usually results in more significant vasomotor symptoms than a natural menopause.
HRT won't kill you - but menopausal women still face a difficult decision
HRT won't kill you - but menopausal women still face a difficult decision | Society | The Guardian
A new analysis of the existing evidence has found a link between hormone replacement therapy HRT and breast cancer. Women's health organisations have said that this is not new evidence but should be used to help women make a decision about menopause treatment. The findings, published in The Lancet , suggest that all types of hormone replacement therapy HRT - besides topical vaginal oestrogen - used to treat menopausal symptoms are associated with an increased risk of breast cancer. This risk may persist for more than ten years after stopping HRT according to the researchers.
HRT does not affect women's death rates
For decades, women have used hormone therapy to ease symptoms of menopause, such as hot flashes and sweating. But well-conducted studies have led many doctors to conclude that the risks of MHT often outweigh the benefits. It does not discuss other possible risks of MHT such as heart disease or stroke.
Numerous studies have looked at the potential health benefits and risks of hormone replacement therapy — particularly the increased risk of breast cancer. For the medical community, piecing it all together is like taking puzzle pieces from different boxes and trying to form them into a picture that makes sense. That can make things even more confusing. Hormone replacement therapy is controversial and complex, but for now it is generally not recommended for women with a history of breast cancer, or those at higher-than-average risk.